---
title: Zona Pellucida Thinning Versus Drilling During Laser-assisted Hatching
nct_id: NCT05311553
overall_status: UNKNOWN
phase: NA
sponsor: National Research Centre, Egypt
study_type: INTERVENTIONAL
primary_condition: Infertility
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05311553.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05311553"
ct_last_update_post_date: 2022-10-21
last_seen_at: "2026-05-12T07:11:27.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Zona Pellucida Thinning Versus Drilling During Laser-assisted Hatching

**Official Title:** Zona Pellucida Thinning Versus Drilling During Laser-assisted Hatching of Human Embryos in Intracytoplasmic Sperm Injection

**NCT ID:** [NCT05311553](https://clinicaltrials.gov/study/NCT05311553)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** National Research Centre, Egypt
- **Conditions:** Infertility
- **Start Date:** 2020-10-01
- **Completion Date:** 2022-12-30
- **CT.gov Last Update:** 2022-10-21

## Brief Summary

Two hundred cycles will be enrolled (100 laser-assisted thinning and 100 laser-assisted drillings).

They will be compared regarding the implantation and clinical pregnancy rates

## Detailed Description

Two hundred cycles will be enrolled (100 laser-assisted thinning and 100 laser-assisted drillings).

All study participants will undergo controlled ovarian stimulation by GnRH agonist long protocol starting from mid-luteal phase. The complete pituitary suppression will be confirmed by serumE2 level less than 30 pg/ml and serum LH level less than 2 mIU/ml, then gonadotropin therapy will be started from day 2 to the day of maturation confirmed by the presence of 3 mature follicles or more, one of them 18 mm; at this time 10000 IU of hCG will be administered then ovum pick up done 36 hours after hCG administration under transvaginal ultrasound guidance Cumulus cell masses around the oocytes will be removed using pull-and-cut denudation pipettes in a 5-well culture dish (MTG, Bruckberg, Germany) containing 27 IU/mL of hyaluronidase.

All oocytes that will be mature at 4-6 h after oocyte collection will be inseminated according to the quality of the spermatozoa and oocytes and the patient's previous IVF history. Fertilization will be confirmed 17-18 h after insemination by the presence of two distinct pronuclei. Zygotes will be cultured in 30-μL micro-drops with a 1-step medium and overlaid with paraffin oil in an atmosphere of 6% CO2, 5%O2, and 95% humidity at 37 °C. The available embryos will be assessed in all patients according to the criteria of equal and regular blastomeres, a viable blastomere number, and fragmentation ratio.

LAH will be conducted using a Laser System with a 1.48-μm diode-laser at 300 m W through thinning or drilling. The embryos will undergo either LAT or LAD in 10- to 20-μL micro-drops consisting of G-MOPS plus medium. The embryos will be fixed in the micro-drops on the inverted microscope. The size of one laser shot will be 5μm in the ZP using the same total number of 3000-μs pulses. In LAT, the goal of the thinning method is to make the outer portion of the outer protective glycoprotein layer thinner. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the ZP thickness. In LAD, the laser opening will be made from the outside to the inside of the ZP.

The laser beam shot towards the ZP above the perivitelline space between two blastomeres to minimize the risk of harming the embryo, under careful control. The embryos in the micro-drop will be washed several times after LAH and then transferred to a 1-well dish (Falcon 353,653, USA) containing G-2 culture medium. LAH was performed 2 to 3 h before embryo transfer. The embryos will be cultured in an atmosphere of 6% CO2, 5% O2, and 95% humidity at 37 °C.

## Eligibility

- **Minimum age:** 25 Years
- **Maximum age:** 40 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients who have a previous ICSI failure, unexplained infertility or male infertility

Exclusion Criteria:

* Patients with hydrosalpinx, pyosalpinx, endometriosis, or uterine fibroids
```

## Arms

- **Zona pellucida thinning** (EXPERIMENTAL) — thinning will be performed without reaching the inner membrane of the Zona pellucida thickness.
- **Zona pellucida drilling** (EXPERIMENTAL) — an opening will be made from the outside to the inside of the Zona pellucida.

## Interventions

- **Zona pellucida thinning** (PROCEDURE) — Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
- **Zona pellucida drilling** (PROCEDURE) — Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.

## Primary Outcomes

- **Implantation rate** _(time frame: at 6 weeks of pregnancy)_ — Implantation rate = the total number of early gestational sacs/the total number of transferred embryos × 100%.

## Secondary Outcomes

- **Clinical pregnancy rate** _(time frame: at 6 weeks of pregnancy)_

## Locations (1)

- Private IVF Center, Cairo, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.private ivf center|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05311553.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05311553*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*